How did WGS outperform forecasts in Q4 2024?

GeneDx Holdings Corp. (WGS) outperformed forecasts in Q4 2024 in several key financial metrics: 1. **Revenue**: WGS reported a revenue of $76.9 million for Q3 2024, which is a 44% increase from the same period in the previous year. This growth in revenue exceeded analyst estimates of $64.98 million for the quarter. 2. **Earnings Per Share (EPS)**: The company reported an EPS of $0.04 for Q3 2024, which is a significant improvement from the loss of $0.82 per share in the same quarter of the previous year. This positive EPS also surpassed analyst expectations of a loss of $0.19 per share. 3. **Net Income**: WGS achieved profitability in Q3 2024, reporting a net income of $1.2 million. This marked a significant milestone for the company and was a result of strategic growth in the pediatric outpatient market and advancements in genomic testing offerings. 4. **Gross Margins**: The company expanded its adjusted gross margins to 64% in Q3 2024, indicating improved operational efficiency and profitability. Overall, WGS's performance in Q4 2024 was bolstered by strong revenue growth, improved profitability, and better-than-expected financial results. These achievements can be attributed to the company's focus on expanding its testing offerings, increasing its market share, and improving its operational efficiency.